What happened
FDA identified violations during a July 2026 review of Royal Peptides LLC’s website. FDA determined that products marketed as Tirzepatide, Semaglutide, Retatrutide, SS-31 (Elamipretide), PT-141, Tesamorelin, and BIMORELIN were drugs based on claims concerning metabolic regulation, weight loss, mitochondrial function, hormone modulation, recovery, and sexual dysfunction. FDA stated that these products were unapproved new drugs because they were not generally recognized as safe and effective for the labeled uses and had no approved applications in effect. Although product labeling included statements such as “for research use only” and “not for human or animal consumption,” FDA cited website evidence indicating intended human drug use. FDA also noted that the firm marketed bacteriostatic water with a peptide guide and calculator that collectively provided means to prepare an injectable drug for human administration. The letter does not describe a manufacturing-site inspection or identify specific CGMP, laboratory, validation, facility, or quality-system deficiencies.
Why it matters
From a pharmaceutical manufacturing perspective, FDA emphasized that injectable products bypass key bodily defenses against toxins and microorganisms and can therefore pose risks of serious harm. The website’s combination of injectable peptide products, bacteriostatic water, and preparation resources raises product-quality and sterility-assurance relevance. However, the letter’s documented violations concern unapproved new drugs and intended-use evidence; it does not report observations establishing deficiencies in aseptic processing, contamination controls, laboratory testing, process validation, facilities, or other manufacturing systems.
Key topics: Unapproved injectable peptide drugs marketed through therapeutic and physiological claims, Research-use disclaimers contradicted by evidence of intended human drug use, Bacteriostatic water, peptide guide, and calculator enabling injectable preparation